Kerbside
Sayali Shirke / 26 Dec 2024/ Categories: DSIJ_Magazine_Web, DSIJMagazine_App, Informed Intelligence, Kerbside, Regular Columns

The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation.
The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation [EasyDNNnews:PaidContentStart]
FABRICATED FOR GROWTH
Vishal Fabrics
BSE Code: 538598
CMP: ₹33.94

Vishal Fabrics, India's largest single-stretch denim manufacturer, is expanding by providing sustainable, high-quality textiles that appeal to both domestic and international fashion brands. Vishal Fabrics Ltd reported strong profits in Q2FY25, highlighting its investment potential. The company posted a 46 per cent YoY growth in net profit to ₹6.50 crore and a 24 per cent YoY rise in revenue, reaching ₹384.78 crore. Strategic cost-reduction measures, cutting quarterly expenditures by over 20 per cent, have bolstered profitability. The company's growth outlook is further strengthened by favourable geopolitical factors, as a potential Trump administration could shift U.S. trade policies to diversify away from Bangladesh and China, increasing demand for Indian textiles. With solid financials and promising international prospects, Vishal Fabrics presents an attractive opportunity for long-term growth.
LIKELY TO REBOUND
Servotech Power Systems
NSE Code: SERVOTECH
CMP: ₹162.51
Servotech Power System Ltd manufactures LED lights and Solar power products. Servotech Power Systems Limited operates as a key manufacturer and supplier of energy solutions, focusing on sustainability and innovation. The stock price of the company is trading near the support of ₹160 and has a likely chance to bounce back. The price has declined for the last 4 consecutive trading sessions. The setup looks perfect for the bullish reversal as the stock is still trading above its 200- day exponential moving average. This optimism adds positivity to the company's stock price. Recently, Servotech Power Systems Ltd rebranded as Servotech Renewable Power System Limited, Emphasising its commitment to Green Energy Solutions.
ENTERPRISE AI PLATFORM LAUNCHED
Intellect Design Arena
BSE Code: 538835
CMP: ₹962.05
Recently, Intellect Design unveiled Purple Fabric, an AIdriven platform for the financial and insurance sectors. Leveraging a 'Multi-Agent' AI system and 'Thinking Brain' tools powered by Large Language Models (LLMs), Purple Fabric streamlines operations like claims settlement and data integration, enhancing customer service and enabling AI-based document management. The platform supports SMEs in building and deploying AI solutions, aiming to expand Intellect Design’s customer base and drive future revenue growth. The company works globally in the fields of Financial Technology for Banking, Insurance and other Financial Services. On the technical front, the stock price has bounced from its 200-DEMA supported by a recent volume spike due to block deals. The stock price of the company has jumped 16 per cent in the last week, whereas on December 23rd, it saw a volume spike of 38.5 times of the 30-day average volume. The stock is in focus light, which suggests positive sentiments.
USFDA APPROVAL
Caplin Point Laboratories
BSE Code: 524742
CMP: ₹2,417.65

Caplin Point Laboratories Ltd has received approval from the US Food and Drug Administration (US FDA) for its Difluprednate Ophthalmic Emulsion, 0.05 per cent eye drops. The drug is a generic therapeutic equivalent version of the reference-listed drug Durezol from Sandoz Inc. The eye drops are a topical corticosteroid used to treat inflammation and pain associated with ocular surgery and in the treatment of endogenous anterior uveitis. Caplin Point Laboratories is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research. The recent US FDA approval gives an optimistic view of the company.
(Closing price as of December 23, 2024)
[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]
To read the entire article, you must be a DSIJ magazine subscriber.
Current print subscribers click here to login
Subscribe now to get DSIJ All Access
[EasyDNNnews:UnPaidContentEnd]